CHRS earnings analysis
What we found in CHRS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Coherus Oncology's Q1 2026 results showed an EPS loss of $(0.25), beating estimates of $(0.27), while revenue of $12.31 million fell short of the $14.35 million estimate. The growth largely stemmed from LOQTORZI, which generated $11.8 million in revenue, marking significant year-over-year growth despite seasonal challenges.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- EPS Beat Estimate
- Reported EPS was $(0.25) vs. estimate of $(0.27), a positive surprise of 0.0741.
- Revenue Growth in LOQTORZI
- LOQTORZI revenue was $11.8 million, up from $7.3 million YoY, a growth of 61%.
- Lower SG&A Expenses
- SG&A expenses decreased to $23.1 million from $26 million YoY.
- Improved Cash Position
- Cash, cash equivalents, and marketable securities were $167 million, down from $172 million, indicating financial stability.
- Free Cash Flow Down
- Free cash flow was $(57.9) million, compared to $(25.8) million YoY, reflecting higher cash burn.
- Cash from Financing
- Net cash provided by financing activities was $53.6 million due to stock issuance.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Revenue Miss vs. Estimates
- Revenue was $12.31 million, missing estimates of $14.35 million, leading to concerns about growth rates.
- High Operating Cash Drain
- Operating cash flow was $(57.9) million, significantly higher cash burn compared to $(25.8) million YoY.
- Default on Convertible Notes
- The risk of default on the substantial $51.64 million debt, including the 2026 Convertible Notes.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.25
- Segment
- LOQTORZI: $11.8M
What they said about what is next.
Outlook deferred to future reports; management expects revenues in 2026 to increase.
The filing reads about the same as the one before it.
What came before.
- 10-K · March 9, 2026
- Coherus Oncology has completed a strategic pivot to an exclusive oncology focus (name change on May 29, 2025) and launched its FDA‑approved PD‑1 product LOQTORZI in the U.S. (launched Jan 2, 2024). Revenue accelerated…
- 10-Q · May 12, 2025
- Coherus reported continuing-operations net revenue of $7,599 (thousand) in Q1 2025, up from $2,308 (thousand) in Q1 2024 driven by LOQTORZI. Gross margin expanded to 65% (from 38%) but the company remains unprofitable…
- 10-K · March 6, 2023
- Coherus (CHRS) positions itself as a biosimilars commercial platform funding a build-out of an immuno‑oncology franchise. Key near-term commercial assets include UDENYCA (pegfilgrastim) with 2022 net sales of $203.8…
- 10-Q · August 4, 2022
- Coherus reported Q2 2022 revenue of $60.151 million, down from $87.643 million in Q2 2021, and a GAAP net loss of $50.150 million (loss per share $0.65). Management reiterated near-term headwinds from increased…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CHRS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever